On May 22, 2026 Foundation Medicine, Inc., a global, patient-focused precision medicine company, reported it will showcase data across its portfolio of high-quality comprehensive genomic profiling tests at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, which will be held May 29-June 2 in Chicago. Data from 14 abstracts will be presented on copy number loss detection, serial circulating tumor DNA (ctDNA) genomic profiling, Foundation Medicine’s proprietary homologous recombination deficiency signature (HRDsig) and more.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
To access the abstracts being presented at the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting, please visit ASCO (Free ASCO Whitepaper).org/abstracts.
Follow Foundation Medicine on LinkedIn, X and Instagram for more updates from #ASCO26 and visit us in person at booth #19145.
Foundation Medicine’s Abstracts at the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting
Abstract Number
Title
Product
Saturday, May 30, 2026
6071
Inferring optimal detection of homozygous loss (homozygous deletion) in head and neck cancer: Associations with HPV status, primary disease site, and clinical outcomes.
FoundationOneCDx
3553
Detecting MTAP loss in liquid biopsies from patients with clinically advanced colorectal cancer (CRC).
FoundationOneCDx, FoundationOneLiquid CDx
4138
Homologous recombination signature (HRDsig) in clinically advanced gallbladder adenocarcinoma (CAGAC): A genomic landscape study.
FoundationOneCDx
3147
Fast-TRACKing precision oncology for rare cancers: A national decentralized trial offering comprehensive genomic profiling and a molecular tumor board.
FoundationOneCDx, FoundationOneRNA, FoundationOneHeme, FoundationOneLiquid CDx
3135
Carcinomas of unknown primary treated with molecularly guided therapies and immune checkpoint inhibitors: A subset from the I-PREDICT N-of-1 Precision Oncology study.
FoundationOneCDx, FoundationOneLiquid CDx
2628
Personalized N-of-1 combinations based on molecular profiles in advanced malignancies: Immunotherapy group analysis of the I-PREDICT N-of-1 precision oncology study.
FoundationOneCDx, FoundationOneLiquid CDx
4124
Beyond fibroblast growth factor receptor 2 (FGFR2) fusions: Mutations and amplifications in intrahepatic cholangiocarcinoma.
FoundationOneCDx
4060
Impact of molecular profile on switch maintenance to paclitaxel plus ramucirumab (PTX-RAM) versus continuation of first-line fluoropyrimidine and oxaliplatin (FOX) chemotherapy (ChT) in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: An exploratory endpoint of the ARMANI phase 3 randomized trial.
FoundationOneCDx
Sunday, May 31, 2026
8551
Serial ctDNA genomic profiling integrated with a networked molecular tumor board in first-line advanced NSCLC: The COPE randomized phase II trial.
FoundationOneLiquid CDx
5044
Genomic landscape of TP53 Y220C–mutated clinically advanced prostate carcinoma (CAPC).
FoundationOneCDx
4619
Neoadjuvant sacituzumab govitecan in patients with muscle-invasive bladder cancer: Final results and biomarker analyses of the SURE-01 trial.
N/A
Monday, June 1, 2026
1121
Homologous recombination deficiency signature (HRDsig+) in older women with advanced breast cancer (ABC).
FoundationOneCDx
2022
Risk of developing brain/central nervous system (CNS) metastases across multiple ERBB2-altered cancer types: Genotype as shaper of phenotype.
FoundationOneCDx
1038
Characterization of genomic alterations between local breast cancers and cutaneous metastases.
FoundationOneCDx
(Press release, Foundation Medicine, MAY 22, 2026, View Source [SID1234666025])